{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:25:37Z","timestamp":1781346337407,"version":"3.54.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>For women at elevated risk of thrombosis, clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis. Oral menopausal hormone therapy increases the risk of venous thromboembolism by 2-fold to 3-fold. Observational studies suggest less thrombotic risk with transdermal therapies and with progesterone over synthetic progestogens (progestins), but the data are limited. Beneficial nonpharmacologic therapies include cognitive behavioral therapy and clinical hypnosis, whereas beneficial nonhormonal pharmacologic therapies include selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. For treatment of the genitourinary syndrome of menopause, vaginal lubricants and moisturizers, low-dose vaginal estrogen, and intravaginal dehydroepiandrosterone are options.<\/jats:p>","DOI":"10.1097\/grf.0000000000000358","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T17:28:46Z","timestamp":1517938126000},"page":"260-268","source":"Crossref","is-referenced-by-count":13,"title":["Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis"],"prefix":"10.1097","volume":"61","author":[{"given":"JOANN V.","family":"PINKERTON","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDRA H.","family":"JAMES","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/01.AOG.0000428645.90795.d9","article-title":"ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus","volume":"166","author":"Curb","year":"2006","journal-title":"Arch Intern Med"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heartjnl-2015-308287","article-title":"Cochrane corner: oral hormone therapy and cardiovascular outcomes in post-menopausal women","volume":"102","author":"Boardman","year":"2016","journal-title":"Heart"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/GME.0000000000000590","article-title":"Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jth.12060","article-title":"The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy","volume":"11","author":"Roach","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1538-7836.2010.03839.x","article-title":"Hormone replacement therapy and the risk of venous thromboembolism: a population-based study","volume":"8","author":"Renoux","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis","volume":"100","author":"Mohammed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/gme.0b013e3181f9f7c3","article-title":"Hormone therapy and recurrence of venous thromboembolism among postmenopausal women","volume":"18","author":"Olie","year":"2011","journal-title":"Menopause"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/gme.0b013e3181e102eb","article-title":"Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen","volume":"17","author":"Canonico","year":"2010","journal-title":"Menopause"},{"key":"R13-20230911","first-page":"CD010407","article-title":"Bioidentical hormones for women with vasomotor symptoms","volume":"8","author":"Gaudard","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0015-0282(16)58328-9","article-title":"Core body temperature during menopausal hot flushes","volume":"65","author":"Freedman","year":"1996","journal-title":"Fertil Steril"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.mpaic.2008.04.009","article-title":"Body temperature and its regulation","volume":"9","author":"Campbell","year":"2008","journal-title":"Anaesth Intensive Care Med"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/13697137.2011.608596","article-title":"Menopausal hot flushes and night sweats: where are we now?","volume":"14","author":"Archer","year":"2011","journal-title":"Climacteric"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0002-9378(99)70437-0","article-title":"Reduced thermoregulatory null zone in postmenopausal women with hot flashes","volume":"181","author":"Freedman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/gme.0b013e31826ce3ed","article-title":"Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial","volume":"20","author":"Elkins","year":"2013","journal-title":"Menopause"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/GME.0000000000000837","article-title":"Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study","volume":"24","author":"Barton","year":"2017","journal-title":"Menopause"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.2044-8287.1996.tb00496.x","article-title":"Evaluation of a four-session cognitive behavioural intervention for menopausal hot flushes","volume":"1","author":"Hunter","year":"1996","journal-title":"Br J Health Psychol"},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/GME.0000000000000836","article-title":"An internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a pilot study","volume":"24","author":"Atema","year":"2017","journal-title":"Menopause"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/GME.0000000000000274","article-title":"Behavioral weight loss for the management of menopausal hot flashes: a pilot study","volume":"22","author":"Thurston","year":"2015","journal-title":"Menopause"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/GME.0000000000000625","article-title":"Exercise training reduces the frequency of menopausal hot flushes by improving thermoregulatory control","volume":"23","author":"Bailey","year":"2016","journal-title":"Menopause"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/1471-0528.13193","article-title":"The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial","volume":"122","author":"Daley","year":"2015","journal-title":"BJOG"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.2016.8012","article-title":"Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis","volume":"315","author":"Franco","year":"2016","journal-title":"JAMA"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2013.08.010","article-title":"Menopausal hot flashes: mechanisms, endocrinology, treatment","volume":"142","author":"Freedman","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/GME.0b013e3182a66aa7","article-title":"Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1345\/aph.1P366","article-title":"Use of gabapentin for the management of natural or surgical menopausal hot flashes","volume":"45","author":"Hayes","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(17)30886-3","article-title":"New pathways in the treatment for menopausal hot flushes","volume":"389","author":"Sassarini","year":"2017","journal-title":"Lancet"},{"issue":"suppl","key":"R32-20230911","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/gme.0b013e31817be9af","article-title":"Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer","volume":"15","author":"Ganz","year":"2008","journal-title":"Menopause"},{"key":"R33-20230911","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"8","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","article-title":"Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks","volume":"159","author":"Martel","year":"2016","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause"},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/jsm.13045","article-title":"Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy","volume":"12","author":"Labrie","year":"2015","journal-title":"J Sex Med"},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/GME.0000000000000613","article-title":"Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial","volume":"23","author":"Fernandes","year":"2016","journal-title":"Menopause"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003081-201806000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:13:07Z","timestamp":1694419987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201806000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000358","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}